溃疡性结肠炎个体化治疗新策略与新进展
New Strategies and Recent Advancements in Individualized Treatment of Ulcerative Colitis
DOI: 10.12677/acm.2026.1662267, PDF,    科研立项经费支持
作者: 姜力宁, 李冬月*：哈尔滨医科大学第一临床医学院，黑龙江 哈尔滨
关键词: 溃疡性结肠炎；个体化治疗；策略；进展；Ulcerative Colitis； Individualized Treatment； Strategy； Progress
摘要: 目的：本文对溃疡性结肠炎(UC)个体化治疗的新策略、新进展进行综述。方法：评价体系包含临床特点、基因检测、生物标志物以及内镜影像学等诸多方面，从而作出准确的决定。结果：新策略包括按照风险分层来确定治疗目标，对靶向药物个体化选择和剂量调整，肠道微生态评价，考虑经济因素，中西医结合方案。结论：近期发展有液体活检及无创预测技术、粪菌移植个体化应用、物理能量疗法、细胞疗法、人工智能和数字化决策支持、药物基因组学联合治疗药物监测等，使UC由原来的阶梯式治疗走向动态、精准、全方位的个体化管理。
Abstract: Objective: This article reviews novel strategies and recent advancements in the individualized treatment of ulcerative colitis (UC). Methods: A multidimensional evaluation framework incorporating clinical characteristics, genetic testing, biomarkers, and endoscopic imaging, among other aspects, is established to enable accurate clinical decision-making. Results: The novel strategies involve determining treatment targets via risk stratification, the individualized selection and dose adjustment of targeted drugs, intestinal microecological evaluation, incorporation of economic factors, and integrated traditional Chinese and Western medicine regimens. Conclusions: Recent technological advances, including liquid biopsy and non-invasive prediction technologies, individualized application of fecal microbiota transplantation, physical energy therapy, cell therapy, artificial intelligence and digital decision support, and pharmacogenomics combined with therapeutic drug monitoring, have facilitated the transition of UC management from the conventional step-up therapy paradigm to dynamic, precise, and comprehensive individualized management.
文章引用：姜力宁, 李冬月. 溃疡性结肠炎个体化治疗新策略与新进展[J]. 临床医学进展, 2026, 16(6): 693-702. https://doi.org/10.12677/acm.2026.1662267

参考文献

[1] Ananthakrishnan, A.N. (2017) Filgotinib for Crohn’s Disease—Expanding Treatment Options. The Lancet, 389, 228-229. [Google Scholar] [CrossRef] [PubMed]
[2] Ponce, M.P., Lagunes, A.G., Aviles, E.C., Almeida del Prado, S.G., Sebastian Ocampo, V.N., Perez, R.Y.L., et al. (2024) S99 Efficacy of Combined Therapy with 5-Aminosalicylic Acids in Patients with Ulcerative Colitis with Isolated Biochemical Activity: A Real-Life Study. American Journal of Gastroenterology, 119, S27-S27. [Google Scholar] [CrossRef] 
[3] Abhishek, A., Nakafero, G., Card, T., Taal, M.W., Grainge, M.J., Aithal, G.P., et al. (2025) Monitoring for 5-Aminosalicylate Nephrotoxicity in Adults with Inflammatory Bowel Disease: Prognostic Model Development and Validation Using Data from the Clinical Practice Research Datalink. BMJ Open Gastroenterology, 12, e001627. [Google Scholar] [CrossRef] [PubMed]
[4] Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., et al. (2021) ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn’s and Colitis, 16, 2-17. [Google Scholar] [CrossRef] [PubMed]
[5] Eggermont, E., Gecse, K., Krugliak Cleveland, N., Petersen, F., Sabino, J., D’Hoore, A., et al. (2026) Ulcerative Colitis: Moving Beyond the Mucosal Dogma. The Lancet Gastroenterology & Hepatology, 11, 163-174. [Google Scholar] [CrossRef] 
[6] Louis, E., Schreiber, S., Panaccione, R., Bossuyt, P., Biedermann, L., Colombel, J., et al. (2024) Risankizumab for Ulcerative Colitis. JAMA, 332, 881-897. [Google Scholar] [CrossRef] [PubMed]
[7] Chuah, K.H., Loo, Q.Y., Hian, W.X., Khoo, X.H., Panirsheeluam, S., Jubri, N.B.M., et al. (2025) Editorial: Heads or Tails in the Treatment of Functional Dyspepsia—Does the Side of the Coin Matter? Authors’ Reply. Alimentary Pharmacology & Therapeutics, 61, 733-734. [Google Scholar] [CrossRef] [PubMed]
[8] Sawaf, B. (2025) Interleukin 12/23 and Interleukin 23 Inhibitors for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. Annals of Gastroenterology, 38, 648-660. [Google Scholar] [CrossRef] 
[9] Miyake, Y., Tanaka, K., Nagata, C., Furukawa, S., Andoh, A., Yokoyama, T., et al. (2024) Case-Control Study of IL23R Rs76418789 Polymorphism, Smoking, and Ulcerative Colitis in Japan. Cytokine, 183, Article ID: 156743. [Google Scholar] [CrossRef] [PubMed]
[10] Goh, L.L., Lim, C.W., Leong, K.P. and Ong, K.H. (2022) TPMT and NUDT15 Testing for Thiopurine Therapy: A Major Tertiary Hospital Experience and Lessons Learned. Frontiers in Pharmacology, 13, Article 837164. [Google Scholar] [CrossRef] [PubMed]
[11] Papamichael, K., Cheifetz, A.S., Melmed, G.Y., Irving, P.M., Vande Casteele, N., Kozuch, P.L., et al. (2019) Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients with Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 17, 1655-1668.e3. [Google Scholar] [CrossRef] [PubMed]
[12] van de Meeberg, M.M., Verheij, E.R., Fidder, H.H., Bouma, G., Huitema, A.D.R. and Oldenburg, B. (2023) Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients with Ulcerative Colitis. Therapeutic Drug Monitoring, 45, 668-675. [Google Scholar] [CrossRef] [PubMed]
[13] Thadiboina, O., Shah, S.S.A., Ray, R., Hack, S.A., Munir, M., Shah, Q., et al. (2025) Effect of Biologic Therapies in Treating Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. Cureus, 17, e85923. [Google Scholar] [CrossRef] [PubMed]
[14] Grova, M., Vitello, A., Mannino, M., Casà, A., Renna, S., Macaluso, F.S., et al. (2023) Role of Ustekinumab in Treatment of Ulcerative Colitis: A Narrative Review. Immunotherapy, 15, 1539-1552. [Google Scholar] [CrossRef] [PubMed]
[15] Ward, M.G., Sparrow, M.P. and Roblin, X. (2018) Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease: Current Data and Future Directions. Therapeutic Advances in Gastroenterology, 11. [Google Scholar] [CrossRef] [PubMed]
[16] Burisch, J., Zhao, M., Odes, S., De Cruz, P., Vermeire, S., Bernstein, C.N., et al. (2023) The Cost of Inflammatory Bowel Disease in High-Income Settings: A Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology, 8, 458-492. [Google Scholar] [CrossRef] [PubMed]
[17] Castellanos, J.M. and Cooney, R. (2025) Global Variability in the Management of Inflammatory Bowel Disease: Towards Context-Specific Strategies. Cureus, 17, e96156. [Google Scholar] [CrossRef] 
[18] Ahuja, D., Park, S., Qi, Y., Patel, S.B., Jairath, V., Xu, R., et al. (2026) Treatment and Outcomes of Crohn’s Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023. Clinical Gastroenterology and Hepatology. [Google Scholar] [CrossRef] 
[19] Rabbitt, L., Keogh, Á., Duane, L., Ferguson, J., Hobbins, A., McGuire, B.E., et al. (2025) A Single‐Centre Analysis of a Biosimilar Switching Programme for Adalimumab in Inflammatory Bowel Disease. British Journal of Clinical Pharmacology, 91, 2628-2635. [Google Scholar] [CrossRef] [PubMed]
[20] Agrawal, M., Kim, E.S. and Colombel, J. (2020) JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. Journal of Crohn’s and Colitis, 14, S755-S760. [Google Scholar] [CrossRef] [PubMed]
[21] Zhang, J., Shi, B., Li, D., Du, Y., Gu, S., Yao, H., et al. (2025) Comparative Study of Chinese Herbal Enema Combined with Mesalazine vs Mesalazine Alone in the Treatment of Ulcerative Colitis: A Randomized Controlled Trial. Journal of the Chinese Medical Association, 89, 61-68. [Google Scholar] [CrossRef] [PubMed]
[22] 中国中西医结合学会. 溃疡性结肠炎中西医结合诊疗专家共识[J]. 中国中西医结合杂志, 2023, 43(1): 5-11.
[23] Tanaka, Y. and Saito, Y. (2021) Importance of NUDT15 Polymorphisms in Thiopurine Treatments. Journal of Personalized Medicine, 11, Article 778. [Google Scholar] [CrossRef] [PubMed]
[24] Liang, Q., Qu, B., Li, C., Hu, Y., Yang, C., Yang, T., et al. (2024) Clinical Characteristics and North-South Differences of Inflammatory Bowel Disease in China: A Cross-Sectional Study and Meta-Analysis. Frigid Zone Medicine, 4, 23-30. [Google Scholar] [CrossRef] 
[25] Wan, J., Shen, J., Wu, X., Zhong, J., Chen, Y., Zhu, L., et al. (2023) Geographical Heterogeneity in the Disease Characteristics and Management of Patients with Inflammatory Bowel Disease, the Preliminary Results of a Chinese Database for IBD (CHASE-IBD). Therapeutic Advances in Gastroenterology, 16. [Google Scholar] [CrossRef] [PubMed]
[26] Li, S., Ney, M., Eslamparast, T., Vandermeer, B., Ismond, K.P., Kroeker, K., et al. (2019) Systematic Review of Nutrition Screening and Assessment in Inflammatory Bowel Disease. World Journal of Gastroenterology, 25, 3823-3837. [Google Scholar] [CrossRef] [PubMed]
[27] Favale, A., Orrù, V., Lutzu, N., Di Petrillo, A., Demurtas, M., Ibba, I., et al. (2026) Optimizing Malnutrition Risk Detection in Inflammatory Bowel Disease: A Longitudinal Analysis of Serial Nutritional Screening Tools. Nutrients, 18, Article 383. [Google Scholar] [CrossRef] 
[28] McCarthy, N.E., Schultz, M. and Wall, C.L. (2025) Role of the Dietitian in the Inflammatory Bowel Disease Multidisciplinary Team. Journal of Gastroenterology and Hepatology, 40, 2190-2196. [Google Scholar] [CrossRef] [PubMed]
[29] Barberio, B., Zamani, M., Black, C.J., Savarino, E.V. and Ford, A.C. (2021) Prevalence of Symptoms of Anxiety and Depression in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 6, 359-370. [Google Scholar] [CrossRef] [PubMed]
[30] 张吉翔, 安萍, 刘传, 等. 中国炎症性肠病患者精神心理和生活质量现状的多中心调查分析[J]. 中华消化杂志, 2022, 42(10): 686-694.
[31] 中华医学会消化病学分会炎症性肠病学组, 中国医师协会精神科医师分会. 炎症性肠病患者精神心理问题诊疗专家指导意见[J]. 中华炎性肠病杂志(中英文), 2026, 10(2): 149-155.
[32] Tian, L., Gao, H., Yao, T., Chen, Y., Gao, L., Han, J., et al. (2025) Interactions between NAD+ Metabolism and Immune Cell Infiltration in Ulcerative Colitis: Subtype Identification and Development of Novel Diagnostic Models. Frontiers in Immunology, 16, Article 1479421. [Google Scholar] [CrossRef] [PubMed]
[33] Heydari, R., Fayazzadeh, S., Shahrokh, S., Shekari, F., Farsad, F. and Meyfour, A. (2024) Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 30, 795-807. [Google Scholar] [CrossRef] [PubMed]
[34] Chenfei, Z., Ainiwaer, Z. and Xiaoling, H. (2025) A Study of the Correlation between the Inflammatory Index and Disease Activity in Ulcerative Colitis. International Journal of General Medicine, 18, 7143-7152. [Google Scholar] [CrossRef] 
[35] Beresford-Jones, B.S., Suyama, S., Clare, S., Soderholm, A., Xia, W., Sardar, P., et al. (2025) Enterocloster clostridioformis Protects against Salmonella Pathogenesis and Modulates Epithelial and Mucosal Immune Function. Microbiome, 13, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[36] Chen, S., Zhang, D., Wu, X., Zhang, F., Cui, B., Huang, Y., et al. (2024) Washed Microbiota Transplantation for Crohn’s Disease: A Metagenomic, Metatranscriptomic, and Metabolomic-Based Study. World Journal of Gastroenterology, 30, 1572-1587. [Google Scholar] [CrossRef] [PubMed]
[37] Pribyl, A.L., Hugenholtz, P. and Cooper, M.A. (2025) A Decade of Advances in Human Gut Microbiome-Derived Biotherapeutics. Nature Microbiology, 10, 301-312. [Google Scholar] [CrossRef] [PubMed]
[38] Thomas, H. (2017) FMT Induces Clinical Remission in Ulcerative Colitis. Nature Reviews Gastroenterology & Hepatology, 14, 196-196. [Google Scholar] [CrossRef] [PubMed]
[39] Doukas, P.G., Doukas, S.G. and Broder, A. (2026) Effectiveness and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis Treatment: A Systematic Review and Meta-Analysis. Digestive Diseases, 44, 85-98. [Google Scholar] [CrossRef] 
[40] Feng, J., Chen, Y., Liu, Y., Lin, L., Lin, X., Gong, W., et al. (2023) Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. Scientific Reports, 13, Article No. 14494. [Google Scholar] [CrossRef] [PubMed]
[41] Maeng, L.S., Yoon, J.H., Chung, B.Y., Seo, K.J., Lee, H.K., Chung, M.G., et al. (2026) Refined Photobiomodulation Therapy Ameliorates Inflammatory Bowel Disease via Modulation of Immune Pathways and Gut Microbiota. Journal of Photochemistry and Photobiology B: Biology, 274, Article ID: 113330. [Google Scholar] [CrossRef] 
[42] Zhu, T., Sun, S., Yang, S., Ji, Y., Wan, H. and Ji, L. (2025) Wheat-Grain Moxibustion Ameliorates Ulcerative Colitis: Suppressing Intestinal Inflammation, Modulating Gut Microbiota, and Restoring Mucosal Barrier Integrity. Journal of Inflammation Research, 18, 12619-12636. [Google Scholar] [CrossRef] 
[43] Ma, Y., Gou, S., Zhu, Z., Sun, J., Shahbazi, M., Si, T., et al. (2024) Transient Mild Photothermia Improves Therapeutic Performance of Oral Nanomedicines with Enhanced Accumulation in the Colitis Mucosa. Advanced Materials, 36, Article ID: 2309516. [Google Scholar] [CrossRef] [PubMed]
[44] 穆剑玲, 刘振栋. 肛肠腔内导入复合能治疗溃疡性结肠炎的探讨[J]. 医疗卫生装备, 2008(6): 79-81.
[45] Hosseini-Asl, S., Mehrabani, D. and Karimi-Busheri, F. (2020) Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges. Journal of Clinical Medicine, 9, Article 3922. [Google Scholar] [CrossRef] [PubMed]
[46] Barbosa, J.C.C., Nuñez, E., Quiceno, L.L., Arroyave, F.A.B., Palacio, L.A. and Halpert-Correa, K. (2025) Safety and Efficacy of Mesenchymal Stem Cell Therapy in Adults with Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials. Cytotherapy, 27, S51. [Google Scholar] [CrossRef] 
[47] Tian, C., Zhang, Y., Yang, M., Xu, H., Zhu, M., Yao, J., et al. (2023) Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges. Journal of Inflammation Research, 16, 2089-2119. [Google Scholar] [CrossRef] [PubMed]
[48] Li, Q., Li, J., Liu, S., Zhang, Y., Liu, J., Wan, X., et al. (2025) Molecular Subtypes and Biomarkers of Ulcerative Colitis Revealed by Sphingolipid Metabolism-Related Genes: Insights from Machine Learning and Molecular Dynamics. Current Issues in Molecular Biology, 47, Article 616. [Google Scholar] [CrossRef] [PubMed]
[49] Lo, B.Z.S., Liu, Z., Bendtsen, F., Igel, C., Vind, I. and Burisch, J. (2021) OP07 Artificial Intelligence Surpasses Gastrointestinal Experts in the Classification of Endoscopic Severity among Ulcerative Colitis. Journal of Crohn’s and Colitis, 15, S007. [Google Scholar] [CrossRef] 
[50] Liu, J., Liu, Y., Zhang, H., Li, Z., Fang, X., He, Z., et al. (2026) Lactate Metabolism-Driven Lactylation: Paradoxical Modulation of Intestinal Inflammation and Malignancy. Journal of Translational Medicine, 24, Article No. 540. [Google Scholar] [CrossRef] 
[51] Min, S., Zhang, X., Liu, Y., Wang, W., Guan, J., Chen, Y., et al. (2025) Personalized Treatment Decision-Making Using a Machine Learning-Derived Lactylation Signature for Breast Cancer Prognosis. Frontiers in Immunology, 16, Article 1540018. [Google Scholar] [CrossRef] [PubMed]
[52] Sinonquel, P., Schilirò, A., Verstockt, B., Vermeire, S. and Bisschops, R. (2023) Evaluating the Potential of Artificial Intelligence in Ulcerative Colitis. Expert Review of Gastroenterology & Hepatology, 17, 145-153. [Google Scholar] [CrossRef] [PubMed]
[53] 中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年∙西安) [J]. 中华炎性肠病杂志(中英文), 2024, 8(1): 33-58.

为你推荐